11/26
02:15 pm
rgen
Repligen (NASDAQ:RGEN) had its "sell (d+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Repligen (NASDAQ:RGEN) had its "sell (d+)" rating reaffirmed by analysts at
Weiss Ratings.
11/26
07:43 am
rgen
Repligen Corporation to Present at Evercore Healthcare Conference [Yahoo! Finance]
Low
Report
Repligen Corporation to Present at Evercore Healthcare Conference [Yahoo! Finance]
11/26
07:30 am
rgen
Repligen Corporation to Present at Evercore Healthcare Conference
Low
Report
Repligen Corporation to Present at Evercore Healthcare Conference
11/21
06:55 pm
rgen
Why Repligen (RGEN) Stock Is Trading Up Today [Yahoo! Finance]
Low
Report
Why Repligen (RGEN) Stock Is Trading Up Today [Yahoo! Finance]
11/20
01:38 pm
rgen
Repligen (NASDAQ:RGEN) had its "sell (d+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Repligen (NASDAQ:RGEN) had its "sell (d+)" rating reaffirmed by analysts at
Weiss Ratings.
11/18
02:58 pm
rgen
Repligen Corporation (RGEN) Presents at 7th Annual Wolfe Research Healthcare Conference Transcript [Seeking Alpha]
Low
Report
Repligen Corporation (RGEN) Presents at 7th Annual Wolfe Research Healthcare Conference Transcript [Seeking Alpha]
11/14
03:29 am
rgen
Repligen: Rare Growth In The Biopharma Supplies Industry [Seeking Alpha]
Low
Report
Repligen: Rare Growth In The Biopharma Supplies Industry [Seeking Alpha]
11/10
01:43 pm
rgen
Repligen Corporation (RGEN) Presents at UBS Global Healthcare Conference 2025 Transcript [Seeking Alpha]
Low
Report
Repligen Corporation (RGEN) Presents at UBS Global Healthcare Conference 2025 Transcript [Seeking Alpha]
11/5
07:45 am
rgen
Repligen (RGEN): Assessing Valuation After Q3 Profits and Raised 2025 Guidance [Yahoo! Finance]
Low
Report
Repligen (RGEN): Assessing Valuation After Q3 Profits and Raised 2025 Guidance [Yahoo! Finance]
11/4
07:30 am
rgen
Repligen Corporation to Present at Upcoming November Conferences
Low
Report
Repligen Corporation to Present at Upcoming November Conferences
11/4
01:07 am
rgen
Low
Report
10/29
10:08 am
rgen
Repligen (NASDAQ:RGEN) was given a new $165.00 price target on by analysts at Canaccord Genuity Group Inc..
Low
Report
Repligen (NASDAQ:RGEN) was given a new $165.00 price target on by analysts at Canaccord Genuity Group Inc..
10/29
06:01 am
rgen
Repligen (NASDAQ:RGEN) was given a new $175.00 price target on by analysts at Barclays PLC. They now have an "overweight" rating on the stock.
Medium
Report
Repligen (NASDAQ:RGEN) was given a new $175.00 price target on by analysts at Barclays PLC. They now have an "overweight" rating on the stock.
10/28
03:01 pm
rgen
Repligen (NASDAQ:RGEN) was given a new $160.00 price target on by analysts at Jefferies Financial Group Inc..
Low
Report
Repligen (NASDAQ:RGEN) was given a new $160.00 price target on by analysts at Jefferies Financial Group Inc..
10/28
07:30 am
rgen
Repligen Reports Third Quarter 2025 Financial Results and Updates Full Year 2025 Financial Guidance
Medium
Report
Repligen Reports Third Quarter 2025 Financial Results and Updates Full Year 2025 Financial Guidance
10/27
04:00 am
rgen
Medium
Report
10/21
11:40 am
rgen
Earnings Preview: Repligen (RGEN) Q3 Earnings Expected to Decline [Yahoo! Finance]
Low
Report
Earnings Preview: Repligen (RGEN) Q3 Earnings Expected to Decline [Yahoo! Finance]
10/19
01:05 am
rgen
Low
Report
10/15
07:30 am
rgen
Repligen to Report Third Quarter 2025 Financial Results
Low
Report
Repligen to Report Third Quarter 2025 Financial Results
10/9
07:56 am
rgen
Is Repligen (RGEN) The Best Healthcare Stock to Buy Now? [Yahoo! Finance]
Low
Report
Is Repligen (RGEN) The Best Healthcare Stock to Buy Now? [Yahoo! Finance]
10/7
01:51 pm
rgen
Repligen (NASDAQ:RGEN) had its price target raised by analysts at Evercore ISI from $155.00 to $175.00. They now have an "outperform" rating on the stock.
Low
Report
Repligen (NASDAQ:RGEN) had its price target raised by analysts at Evercore ISI from $155.00 to $175.00. They now have an "outperform" rating on the stock.
10/4
09:12 am
rgen
Is Repligen's Recent 18% Price Surge Justified After Broad Biotech Rally? [Yahoo! Finance]
Low
Report
Is Repligen's Recent 18% Price Surge Justified After Broad Biotech Rally? [Yahoo! Finance]
10/3
06:38 am
rgen
Repligen (NASDAQ:RGEN) was upgraded by analysts at Hsbc Global Res to a "strong-buy" rating.
Low
Report
Repligen (NASDAQ:RGEN) was upgraded by analysts at Hsbc Global Res to a "strong-buy" rating.
10/2
08:02 am
rgen
Repligen (NASDAQ:RGEN) had its "overweight" rating reaffirmed by analysts at Barclays PLC.
Low
Report
Repligen (NASDAQ:RGEN) had its "overweight" rating reaffirmed by analysts at Barclays PLC.
10/1
10:43 am
rgen
Repligen higher as HSBC initiates at Buy on growth prospects [Seeking Alpha]
Low
Report
Repligen higher as HSBC initiates at Buy on growth prospects [Seeking Alpha]